
Novo Nordisk’s primary business area, dubbed Diabetes Care, fared worse than expected in the second quarter of 2022. The Ozempic drug once again generated higher-than-expected growth but Rybelsus disappointed compared to analyst estimates, the firm’s accounting report for the period showed Wednesday.
Overall diabetes revenue at Novo Nordisk totaled DKK 32.4bn (USD 4.4bn) in Q2 compared to DKK 26bn (USD 3.6bn) in the same period last year. This falls short of the analyst consensus estimate of DKK 32.6bn (USD 4.5bn) calculated by the pharmaceutical firm before the report was released.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app